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Introduction
The element manganese (Mn) is critical for almost all forms of life, yet in excess can be extremely toxic. In humans and mouse models, Mn toxicity has been linked to Parkinsonian-like neurodegeneration including a condition known as manganism (Aschner et al., 2009; Dieter et al., 2005; Kwakye et al., 2015) . This critical axis of essentiality toxicity demands strict regulation of Mn in almost all biological systems. Although some is known about Mn regulation in the gut, very little is known about its regulation at the neuronal level. Understanding the complexity of this system is caused, in part, by the fact that most metal transporters are highly promiscuous, capable of transporting many different ions. Some of these include transporters divalent metal transporter-1 (DMT-1), transferrin, Ferroportin, Huntingtin interacting protein (HIP)14, PARK9 and calcium channels. In addition, few of these exclusively transport Mn at relevant concentrations aside from some possible exceptions such as SLC30A10 (Horning et al., 2015) .
The STHdh immortalized murine neuroprogenitor cell model is an ideal system to study neuronal Mn biology as the cellular fura 2 manganese extraction assay (CFMEA) was developed and rigorously tested in this system (Kwakye et al., 2011) . Cellular Mn uptake in the STHdh cells is robust and can occur at levels which are sub-toxic, yet exhibit sensitive activation of cell signaling pathways which are much less responsive in other neuronal systems. In addition, our previous findings on Mn-induced activation of AKT and ATM/p53 were conducted primarily using in this model system (Tidball et al., 2015a; Williams et al., 2010a) .
Mn is necessary for the activity of many biologically indispensable enzymes including manganese superoxide disumutase (MnSOD), arginase, and glutamine synthetase and sufficient for the activation of many more including ataxia telangiectasia mutated (ATM) kinase. Both toxic and sub-toxic levels of Mn are known to stimulate several critical cell signaling pathways implicated across a broad variety of biological processes and disease states (Tidball et al., 2015b; Bae et al., 2006; Cordova et al., 2013 Cordova et al., , 2012 Dearth et al., 2014; Dormond et al., 2004; Exil et al., 2014; Srivastava et al., 2016; Williams et al., 2010b; Ma et al., 2015; Wan et al., 2014; Guilarte, 2010a; Guilarte et al., 2008) . In this study, we focus particularly on p53 and AKT/mTOR pathways that have not only been studied in the context of Mn toxicity but also extensively implicated in several neurodegenerative diseases including Parksinson's and Huntington's disease (Humbert et al., 2002; Humbert and Saudou, 2003; Lopes et al., 2014; Naia et al., 2015; Ribeiro et al., 2014; Yamamoto et al., 2006; Lee et al., 2014; Sarkar et al., 2008; Williams et al., 2008) . Activation by Mn allows ATM to phosphorylate P53, a tumor suppressor gene (Chan et al., 2000) . P53 functions most commonly to direct DNA repair, cell cycle arrest, and apoptosis-processes highly implicated in both cancer and neurodegeneration. AKT/mTOR pathways-canonically activated by upstream growth factors-are implicated across a wide variety of processes spanning glucose metabolism, cell proliferation, autophagy and apoptosis. Presently, the regulation of Mn within neurons is a "black box" with little known about how Mn is transported or sequestered within the brain. Thus, understanding the complete implications of Mn homeostasis on Mn-responsive proteins and processes or even how Mn activates specific proteins has been difficult to study. We sought to study how Mn acts to stimulate the aforementioned cell signaling pathways in a murine striatal neuroprogenitor model and whether these Mn-responsive cell signaling pathways could also modulate Mn levels within these cells.
Methods and materials

Inhibitors and antibodies
The small molecule inhibitors (KU55933, KU60019, NU7441, and LY294002) were purchased from Tocris, reconstituted in DMSO, and stored at À80
prior to experiments. The rapamycin and Torin 2 were generous gifts from Dr. Kevin Ess. Antibodies were purchased from Cell Signaling Technologies (p-AKT (Ser473) #4060, p-p53 (Ser15) #9286, p-S6 (Ser235/236) #2211, actin #4968S). Neuro2A, HEK293, ST14A, and mouse embryonic fibroblasts (MEF) were cultured in DMEM with 4.5 g/L glucose, L-glutamine, and sodium pyruvate with 10% FBS and penicillin/streptomycin. All cells were grown at 37 C and 5% CO 2 . MEF cells were harvested from WT BL6-c57 mice between E12.5-E13.5. For CFMEA experiments, 3 separate MEF lines were used.
Cell culture
Islet-1 striatal neuroprogenitors derived from hiPSCs
Islet-1 hiPSC-derived neuroprogenitor cells were differentiated and harvested for protein exactly as previously described using three separate healthy control patient iPSCs (Tidball et al., 2015a) . Protein lysates were frozen prior to BCA protein quantification and preparation for the Simple Wes assay. Additionally, a subset of cells was fixed with ice-cold methanol for 15 min at À20 C and immunocytochemistry was performed to ensure all cultures expressed Islet-1.
Immunoblot analysis
Protein samples were prepared by scraping cells into ice-cold PBS, centrifuging, and adding RIPA buffer containing protease (Sigma-Aldrich, St. Louis, MO) and phosphatase inhibitor cocktails 2 & 3 (Sigma, Sigma-Aldrich, St. Louis, MO) to the pellet. After gentle homogenization, cells were centrifuged at 4 C for 10 min at 20,000g. The resulting DNA containing pellet was removed from the lysate, and the protein concentration was quantified using the BCA assay (Peirce Technologies) with a BSA standard curve. Samples were mixed with 5 x SDS loading buffer containing 1% 2-mercaptoethanol and boiled for 5 min. 15 mg of protein was loaded for each sample onto a 4-15% pre-cast gel SDS-PAGE gel (BioRad, Hercules, CA) and run at 90 V for 120 min. The protein bands were then transferred onto nitrocellulose membranes using iBlot Gel Transfer Device (Life Technologies). The remaining gel was stained with IRDye Blue protein stain (LI-COR, Lincoln, NE). Since the gels retained $1/3 of the original protein after transferring with the iBlot, the stained gels were imaged on the Li-Cor Odyssey Imaging System and the intensity of the entire lane from $150-20 kDa was quantified. This value was used to normalize the values of immunostained bands. The membrane was blocked in Odyssey Blocking Buffer for one hour prior to the addition of the primary antibodies. The primary antibodies were diluted 1:1000 in Odyssey Blocking Buffer containing 0.1% TWEEN and incubated overnight. After washing 5 times for 5 min in TBST, membranes were incubated with secondary antibodies at 1:10,000 (LiCor, Lincoln, NE) for 1 h. Membranes were imaged using the Li-Cor Odyssey Imaging System, and quantification was performed using Image Studio Lite (LiCOR, Lincoln, NE).
In-cell western assay
Cells were plated in 96-well mClear black-walled plates (Greiner Bio-One, Frickenhausen, Germany) at the appropriate density for the particular line. After exposing cells to toxicants, cells were washed once in room temperature PBS (without calcium and magnesium). The cells were then fixed with 4% paraformaldehyde in PBS for 30 min at room temperature, washed 5 times for in PBS with 0.1% Triton-X 100, and blocked for 1.5 h in 150 mL of Odyssey blocking buffer. Cells were then incubated with primary antibody at 1:400 in Odyssey blocking buffer (LiCor, Lincoln, NE) with 50 mL per well for 2.5 h. After washing 4 times in PBS with 0.1% Tween-20 for 5 min, cells were incubated for 1 h in the appropriate LiCor IRdye800 secondary antibody at 1:800 dilution in Odyssey blocking buffer along with 1:500 of CellTag normalization dye (LI-COR, Lincoln, NE). An additional round of 5 washes for 5 min in PBS with Tween-20 was performed after which all buffer was removed. Plates were imaged with the Li-Cor Odyssey Imaging System and intensities were calculated for each well with Image Studio software. Cultures that were not incubated with primary antibodies served as background. Antibody signals were normalized using the CellTag signal (a measure of total cells).
Cellular Fura-2 Manganese Extraction Assay (CFMEA)
CFMEA was performed as described previously (Tidball et al., 2015a) .
CellTiterBlue cytotoxicity assay
Mouse striatal cells (STHdh
Q7/Q7
) were grown on 96-well plates. The day after replating, the cells were exposed to toxicants in the cell-type appropriate medium. After 22 h of exposure, 20 mL of CellTiterBlue reagent (Promega, Madison, WI) was added to each well. Prior to this addition, cell lysis buffer was added to several wells to provide an accurate fluorescence background for 0% viable cells. The plates were then incubated for 2 h at 33 C. Fluorescence was measured using excitation of 570 nm and emission of 600 nm on a microplate reader.
Protein simple wes protein expression quantification
The Protein Simple Wes (Protein Simple, San Jose, California) was performed on day 11 Islet-1 striatal neuroprogenitors derived from hiSPCs. The assays were performed following manufacturer's guidelines using the 12-230 kD kit: separation time = 25 min, voltage = 375volts, antibody diluent time = 5 min, primary incubation time = 30 min, and secondary antibody time = 30 min 5ul of protein lysate at 1ug/uL was used per run, per sample. The p-p53 antibody was diluted 1:50 and actin was diluted 1:200 in 0.1X sample buffer provided by the manufacturer. Expression is given as relative chemiluminescence signal area under the curve at a particular peak.
Graphing and statistical analysis
To allow for appropriate post-hoc statistical analysis, western blots comparing SMIs vs Vehicle were normalized to vehicle. For this data, 95% confidence interval testing (GraphPad Prism 7) analysis was performed. Graphs comparing Mn-treated to SMI + Mn were normalized to vehicle. For this data, t-tests were performed using Microsoft Excel. All graphs were made using GraphPad Prism 7.
Results
KU55933 and KU60019 do not completely inhibit p-p53 in wildtype STHdh cells
Recently, our lab has shown that ATM kinase is responsible for the phosphorylation of p53 on serine 15 (p-p53) following exposure to sub-toxic (200 mM) concentrations of Mn in human induced pluripotent stem cells (hiPSCs) differentiated into striatallike neuroprogenitors. We found that 1 mM KU55933 completely inhibits phosphorylation of p53 at serine 15 following a 200 mM Mn exposure in hiPSC-derived Day 11 striatal neuroprogenitors. However, in E14-derived mouse striatal neuroprogenitors (STHdh), KU55933 does not completely inhibit p-p53 or p-H2AX expression ($50% decrease), two targets of ATM, following a 24 h, 50 mM Mn exposure even at 20 mM, a concentration far beyond the reportedIC 50 for ATM (Supplemental Fig. S1A ). Furthermore, KU60019, a more potent and specific derivative of KU559933, was unable to block Mn-induced p-p53 activity at 10 mM as measured by In-cell western (Supplemental Fig. S1B ) (Golding et al., 2009) . Previous work in this cell model also revealed that 20 mM KU55933 was unable to completely block H 2 0 2 (1 h) induced p-p53 activity but could block the DNA mutagen neocarzinostatin (1 h) induced p-p53 activity, suggesting that other kinases are responsible (at least, in part) for Mn induced pp53 expression (Tidball et al., 2015a) .
NU7441 and LY294002 inhibit p-p53 activation and Mn uptake at concentrations which inhibit PI3K
Given the contradictory results between the hiPSC and STHdh systems, we sought to explore whether alternative kinases act similarly to ATM in the STHdh cells to phosphorylate p53 at serine 15. Additionally, a previous study revealed that KU55933 can inhibit DNApk, mTOR, and PI3K at 2.5 mM, 9.3 mM and 16.6 mM, respectively (Hickson et al., 2004) . In order to determine if any of these kinase signaling pathways are responsible for Mn-induced phosphorylation of p53, we utilized several small molecule inhibitors (SMIs) with overlapping IC 50s for DNApk, mTOR, ATM, and PI3K (Table 1) . As kinase inhibitors are notoriously nonspecific, we used other PIKK inhibitors that also inhibit PI3K at defined IC 50s , providing additional validation of our studies. In this way, we used overlapping, yet specific IC 50s to exclude particular protein targets (ie: If KU55933 were to inhibit Mn-induced p-p53 at 2.5 mM, but NU7441 does not inhibit p-p53 at 14 nM and LY294002 does not inhibit at 1.2 mM, then DNApk inhibition would likely not be responsible for reduced p-p53-see Table 1 ). Thus, we first exposed STHdh cells for 24-h with 50 mM Mn and either NU7441 or LY294002. NU7441 is known to inhibit DNApk at 14 nM, but also inhibits PI3K at 5 mM. LY294002 inhibits PI3K at 7 mM. Upon treatment with Mn and NU7441/LY294002, a $50% decrease in p-p53 levels was observed with 5 mM NU7441 and 7 mM LY294002, mirroring the effects of 20 mM KU55933 on p-p53 expression (Fig. 1A,B ) (Leahy et al., 2004; Vlahos et al., 1994) . At these concentrations, NU7441 and LY294002 do not inhibit ATM. Furthermore, NU7441 and LY294002 reduced Mn-induced p-p53 levels in a dose-dependent manner with an approximate IC 50 near their defined IC 50 for PI3K (Fig. 1C, D) .
3.3. LY294002, NU7441, KU55933, and KU60019 can reduce Mn uptake at concentrations near the IC 50 for PI3K
It was surprising that PI3K inhibition reduced Mn-induced pp53 expression, as PI3K is not directly linked to the activation of ATM/p53 (though downstream signaling members of PI3K-AKT and mTOR-have been linked to p53 regulation). We hypothesized that these inhibitors (LY294002, NU7441, KU55933, and KU60019) could be acting by reducing Mn uptake itself, thus reducing the intracellular pool of Mn and leading to a decrease in p-p53. Utilizing the cellular fura-2 Mn extraction assay (CFMEA), we examined Mn uptake after a 24-h dual exposure/treatment with 50 mM Mn and an SMI. LY294002, NU7441, KU55933, and KU60019
were able to reduce Mn uptake only at concentrations which neared the IC 50 for PI3K inhibition (mTOR inhibitors had no effect on Mn uptake even at levels exceeding the IC 50 for mTOR) (Fig. 2) . The two ATM inhibitors (KU55933 and KU60019) were able to inhibit Mn-induced p-p53 expression only at concentrations exceeding the IC 50 for ATM (Fig. 2C, D) . These data suggest that the observed reduction in Mn-induced p-p53 expression by these SMIs is a result of decreased Mn uptake.
3.4. LY294002 and NU7441 can reduce Mn-induced p-AKT and p-S6 expression at concentrations near the IC 50 for PI3K
Mn exposure has been known to activate AKT and mTOR pathways in addition to ATM/p53 (Dieter et al., 2005; Bae et al., 2006; Cordova et al., 2013 Cordova et al., , 2012 Dearth et al., 2014; Dormond et al., 2004; Exil et al., 2014; Srivastava et al., 2016 Srivastava et al., , 2013 Williams et al., 2010b; Hiney et al., 2011) . STHdh cells were exposed with 50 mM Mn and either NU7441, LY294002, or Rapamycin for 24-h then expression levels of p-AKT(Ser473), and p-S6(Ser235/236) were analyzed by western blot. P-AKT(Ser473) expression levels were greatly reduced after exposure with NU7441 and LY294002 ($3 fold) while Rapamycin was unable to inhibit p-AKT levels (Fig. 3A, C) , consistent with mTORC1 signaling being downstream of AKT. p-S6 (Ser235/236) levels, indicative of mTOR activity, were reduced to the greatest magnitude after NU7441 or LY294002 exposure, but also after exposure with 1 nM rapamycin (Fig. 3B, D) . We examined the effects of LY294002, NU7441, and Rapamycin without Mn (from the same set as data in Fig. 3A-D) which show that mTOR is blocked by LY294002, high concentrations of NU7441 which should inhibit PI3K, and rapamycin. LY294002 and NU7441, but not rapamycin, reduced expression of p-AKT, consistent with their inhibitory cross-reactivity for PI3K. None of the inhibitors blocked basal p-p53 expression (Supplemental Fig. S2 ). We observed similar phospho-protein trends after 3 h exposures but neither LY294002 nor NU7441 could reduce Mn uptake after only 3 h (Supplemental Fig. S3 ). These results confirm that the SMIs are inhibiting the pathways we expected, further confirming a role for PI3K in Mn homeostasis and Mn-dependent cell signaling in this STHdh cell line. Coomassie stain (total protein, below) was used as a loading control. B) Quantification of (ser15) from western blots (n = 3). Error bars = SEM.). All Mn + SMI values were compared with Mn alone by t-test. *p < 0.05, **p < 0.01. C, D) Dose-response curve for Mn-induced p-p53 expression using LiCor In-Cell Western assay with increasing concentrations of LY294002 or NU7441 (n = 2 with 5 technical replicate wells, error bars represent SD of all 10 wells). Red arrows denote reported IC 50 for respective SMI. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.) Fig. 2 . LY294002, NU7441, KU55933, and KU60019 can reduce Mn uptake at concentrations near the IC50 for PI3K. A-D) Cellular Fura-2 manganese extraction assay (CFMEA) was used to quantify 24-h Mn uptake with increasing concentrations of NU7441, LY294002, KU55933, or KU60019. (n = 3 with 6 technical replicate wells, error bars represent SD of 3 biological replicates). Red arrows denote reported IC 50 for respective SMI. E) CFMEA after 24-h Mn and/or mTOR inhibitors "mTORi" (Torin or Rapamycin). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.) 
LY294002 is unable to reduce Mn uptake in other cell lines or during shorter exposures
We next investigated whether the inhibition of PI3K also had an effect on Mn uptake in other cell models aside from STHdh. Additionally, given that PI3K is a critical protein involved in both endocytic and exocytic trafficking as well as activation of AKT, we wanted to examine whether the observed effects on Mn uptake are driven by cellular toxicity. We exposed STHdh cells with Mn and/or LY294002, NU7441, KU55933, or KU60019 for 24 h and used Cell Titer Blue to measure cell viability. Cell viability in the STHdh was relatively unchanged by exposure/treatment with Mn and/or inhibitors (Fig. 4B, C) . However, while STHdh cells exhibit robust decreases in net Mn uptake following dual Mn and PI3K inhibitor exposure with limited toxicity, PI3K inhibition was unable to reduce Mn uptake in any of the other cell lines tested (ST14A, Mouse embryonic fibroblasts (MEF), hiPSC differentiated striatal neuroprogenitors) (Fig. 4A, D) . We also tested whether LY294002 and NU7441 could inhibit PI3K signaling (p-AKT, p-S6 expression) during 3 or 24 h exposures in Neuro2A and HEK293 cells. We found that LY294002 blocks basal ($50%) and Mninduced AKT/mTOR activity in these cell lines after 3 or 24 h, but both LY294002 and NU7441 do not block Mn uptake (Figs. 5 and 6 Supplemental Fig. S4 ). These data suggest the mechanism for PI3K inhibition on net Mn uptake is not sufficiently explained by AKT or S6 signaling and is specific to the unique biology of the STHdh cell line.
LY294002 inhibits p-p53 activity in STHdh cells by reducing intracellular Mn
As we observed decreased net Mn uptake with LY294002 and Mn co-exposure, we postulated that the PI3K inhibitor decreases Mn-induced increased p-p53 levels by decreasing intracellular Mn levels. Consequently, we assessed the relationship of intracellular Mn levels and p-p53 levels at a range of Mn exposures (25, 37.5, and 50 mM) with and without LY294002 (7 mm). LY294002 reduced intracellular Mn and p-p53 expression by 50% at all Mn concentrations. Furthermore, a linear regression of Mn vs. p-p53 activity reveals a high correlation between Mn levels and Mninduced p-p53 expression (R 2 = 0.9649, 0.9860, and 0.9775 for Mn, Mn and LY294002, combined Mn and Mn LY294002 values, respectively) ( Fig. 7A-C) . In addition, ANCOVA analysis was performed on this data to examine whether these linear regression lines were statistically different from each other. ANCOVA revealed that the slopes of the regression lines were not statistically different and were heavily correlated (R 2 = 0.98, p = 0.218, df = 6, F = 1.98). These exposures resulted in slight reductions in cell viability, but not enough to account for the observed changes in Mn uptake and p-p53 expression (Fig. 7D ). Together these data suggest p-p53 acts as a surrogate rheostat of Mn levels within these cells. Together, these findings confirm our hypothesis that LY294002 reduces intracellular Mn, indirectly reducing activation of p-p53 by Mn, rather than inhibiting direct phosphorylation of p53 by PI3K or a downstream partner. Lastly, we sought to test whether LY294002 inhibits Mninduced increases in p-p53 in a cell line where LY294002 is unable to reduce Mn uptake (day 11 hiPSC-derived Islet-1 striatal neuroprogenitors). Dual LY294002 and 200 mM Mn exposure did not block Mn-induced p-p53 activity (p = 0.145) in three patientderived cell lines (Fig. 8B, C) . As a positive control, KU60019 was able to partially reduce Mn-induced p-p53 levels at 1 mM (p = 0.047), but to a lesser degree than previous reports of KU55933 at 1 mM in these same cells. The effect of KU55933 was confirmed in this study (Fig. 8A) . Together, these data suggest PI3K plays a unique role in Mn uptake, and thus Mn-induced cell signaling activity, in STHdh cells but not other cell lines-even those of striatal lineage.
Discussion
We have demonstrated that the SMIs KU-55933, NU-7441, and LY294002 can potently inhibit Mn uptake (near $50% for all three SMIs) in a mouse striatal neuroprogenitor model at concentrations consistent with inhibition of their shared target, PI3K. KU-60019, to the best of our knowledge, has not been reported to inhibit PI3K, though KU55933 is known to inhibit PI3K at concentrations of 16.6uM or higher. Our data suggest that KU-60019 also inhibits PI3K at an approximate IC 50 of 10 mM (Fig. 2D) , if it reduces net intracellular Mn uptake in STHdh cells via the same mechanisms the other SMIs used. This conclusion is consistent with the relative inhibition of Mnuptake for KU-60019 being almost identical ($50%) to the established PI3K inhibitors. Our data suggest KU-55933, NU-7441, LY294002, and KU-60019 do not decrease net Mn levels via reduced cell viability, since effective concentrations only showed about a 15-20% reduction in viability, even in the presence of Mn À this was insufficient to account for the over 50% decrease in Mn uptake seen with these inhibitors. LY294002, a specific inhibitor of PI3K, is effective at reducing net Mn uptake at a concentration consistent with PI3K inhibition from the literature (7 mM) (Fig. 3) (Bar et al., 2005) . Likewise, the concentrations at which NU-7441 and KU-59933 were found to be effective at inhibiting Mn uptake and p-p53 expression (5 mM and 20 mM, respectively) are also consistent with inhibition of their shared off-target, PI3K
(inhibited at 5 mM and 16.6 mM, respectively) ( Table 1, Fig. 3 ). mTORC1 is also a shared target between all four inhibitors, but use of mTORC1 inhibitors rapamycin or torin at concentrations equal to or surpassing their IC 50s for mTORC1 had no effect on Mn uptake (Fig. 2E) (Liu et al., 2013; Thoreen et al., 2009 ).
As LY294002 could not reduce Mn uptake in the other cell lines tested, the role of PI3K may be uniquely tied to Mn homeostasis in STHdh cells. Perhaps STHdh cells lack a compensatory pathway for PI3K that is preserved in the other cells tested, making STHdh Mn homeostasis exquisitely sensitive to PI3K inhibition. It is also possible the STHdh cell line, because its specific lineage, neuronal maturity, origin, etc. expresses a specific transporter which is PI3K dependent. Alternatively, while LY294002 is reported to be specific to PI3K at the concentrations used, it is possible that LY294002 is also inhibiting another protein, similar to PI3K, in STHdh cells and causal in the observed effects. Reported IC 50s of LY294002 for PI3K have been somewhat variable between studies and cell lines (1-10 mM). These reports have shown that LY294002 can also inhibit other targets (including mTOR and DNApk) at concentrations lower than 10 mM (Vlahos et al., 1994; Brunn et al., 1996; Ballou et al., 2007) . However, in this study we utilized more specific inhibitors (Rapamycin and NU7441) with overlapping IC 50s , suggesting that neither mTOR nor DNApk are responsible for the effect. Collectively, available data cannot exclude the possibility that a specific off-target for LY294002, aside from mTOR and DNApk, may be uniquely expressed in STHdh cells and responsible for Mn uptake in these cells and not in other cell lines. However, this specific off-target would have to be coincidentally inhibited by four different inhibitors at all their reported IC 50s for PI3K.
While our study does not elucidate the mechanism by which PI3K is modulating Mn uptake, our results do offer some insight. PI3K inhibition only results in reduced Mn uptake in STHdh cells after 24 h, which could indicate an epigenetic alteration or a transcriptional-to-translational cascade is occurring in these cells after the addition of PI3K inhibitors, reducing Mn uptake (Fig. 2,  Supplemental Fig. S3 ). However, these four inhibitors do inhibit basal and Mn-induced p-AKT and p-S6 expression at 3 h, even in cell lines in which they do not affect Mn uptake (Figs. 5 and 6, Supplemental Fig. S4 ). Thus, inhibition of AKT and mTOR is not responsible for the reduction in Mn uptake observed upon exposure with PI3K inhibitors. Furthermore, the results suggest that Mn-induced p-AKT and p-S6 signaling are PI3K-dependent.
Our observations reported here raise some very novel and interesting questions. How is PI3K exerting its role on Mnhomeostasis in the STHdh model? What types of transport/ transporters is PI3K working through to impinge on Mn homeostasis? Given the inherent difficulty in studying Mn homeostasis due to poorly understood transport and sequestration, understanding how PI3K is capable of such a dramatic effect on Mn uptake could lead to the discovery of other, more commonly shared, pathways of Mn homeostasis. Considering PI3K's downstream role in endocytosis via signaling of PIP2-PIP3, a reasonable hypothesis is that PI3K signaling upregulates endocytosis of a specific, unknown Mn-receptor on the cell surface. This type of transport would mirror clathrin-mediated endocytosis of iron, another biologically indispensable heavy metal. A previous study by our lab has shown that saturating clathrin-mediated uptake with iron, thus blocking transferrin-mediated Mn uptake, only reduces Mn toxicity by $10% STHdh cells (Williams et al., 2010a ). This suggests clathrin-mediated endocytosis cannot fully explain the effect of PI3K inhibition on Mn uptake. Regardless, Mn uptake has directly been associated with intracellular toxicity via increased generation of reactive oxygen species and mitochondrial dysfunction and has been recognized as a potent neurotoxicantparticularly in dopaminergic neurons (Brouillet et al., 1993; Guilarte, 2010b; Neal and Guilarte, 2013; Zhang et al., 2011 Zhang et al., , 2004 Zhang et al., , 2003 An et al., 2012; Gavin et al., 1999; Gunter et al., 2009; Malecki, 2001 ). This study suggests that PI3K may play a role in neuronal Mn homeostasis, offering a potential target/pathway which can be furthered studied in the context of Mn toxicity [BMR1] . LY294002 causes some toxicity, which is exacerbated by addition of toxic concentrations of Mn and, thus, does not reduce overall intracellular toxicity. In principle, however, using other small molecules to target pathways/proteins (possibly including PI3K) that can reduce Mn uptake in the context of toxic Mn exposures could be valuable tools for studying future therapeutics.
Similarly, given PI3K is upstream of AKT/mTOR, it is possible that PI3K is responsible for perpetuating an upstream signal leading to the activation of autophagy via the mTOR pathway, which may then act to degrade Mn-laden proteins, releasing Mn into a useable pool for the cell. However, the lack of effect on Mn uptake by rapamycin and Torin, known mTOR inhibitors, do not support this hypothesis. If PI3K does truly exert such potent control on Mn homeostasis, it could also control activation of the wide array of Mn-dependent and Mn-activated enzymes and thus, Mndependent cell signaling. In this study, we have shown that p-p53 expression is tightly correlated to Mn status in this cell line and that PI3K can act to modulate this ion-protein interaction (Fig. 7) . Furthermore, PI3K's protein-serine kinase activity is Mn-dependent while its lipid activity is inhibited by Mn (Chauhan et al., 1995) . Indeed, responding as a Mn "sensor", PI3K could function to regulate not only the ATM/p53 and AKT/mTOR pathways, but many other Mn-responsive processes within the cell, in response to intracellular Mn levels. 
